Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

First trimester serum screening for Down's syndrome

N J Wald1, A Kennard, A K Hackshaw

  • 1Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Medical College, St. Bartholomew's Hospital, University of London, U.K.

Prenatal Diagnosis
|December 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pregnancy-associated plasma protein-A truncation limits in antenatal screening for trisomy 18.

Journal of medical screening·2017
Same author

Mortality from aortic stenosis: prospective study of serum calcium and phosphate.

Journal of internal medicine·2017
Same author

Prevention of neural tube defects in the UK: a missed opportunity.

Archives of disease in childhood·2015
Same author

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.

Thorax·2015
Same author

Presentation of meta-analysis plots.

Journal of medical screening·2015
Same author

Is the area under an ROC curve a valid measure of the performance of a screening or diagnostic test?

Journal of medical screening·2014
Same journal

Genomic Landscape and Perinatal Outcomes of Fetal Polydactyly: A Retrospective Cohort Study Integrating CNV-seq and Trio-ES.

Prenatal diagnosis·2026
Same journal

Detecting Androgenetic Origin of the Genome via Single-Nucleotide Polymorphism-Based Cell-Free DNA Screening in Dichorionic Diamniotic Twin Pregnancies With Complete Hydatidiform Moles and a Coexisting Normal Fetus: A Three-Case Report.

Prenatal diagnosis·2026
Same journal

Structural Variation Sequencing of 26 Amniotic Fluid Samples With Partial Gene Duplications and Postnatal Follow-Up of the Fetuses.

Prenatal diagnosis·2026
Same journal

Prenatal Spectrum of COL2A1-Related Spondyloepiphyseal Dysplasia Congenita: A Review and Two Case Reports.

Prenatal diagnosis·2026
Same journal

Association of Fetal Cerebrovascular Resistance and Neurodevelopment in Congenital Heart Disease: A Physiology-Based Analysis.

Prenatal diagnosis·2026
Same journal

Prenatal Genetic Testing for Beckwith-Wiedemann Syndrome: Considerations, Challenges and Observations (A Real-World Study).

Prenatal diagnosis·2026
See all related articles

Early Down's syndrome screening at 10 weeks uses pregnancy associated placental protein A (PAPP-A) and free beta-hCG. While promising, current data is insufficient for routine practice.

Area of Science:

  • Prenatal screening
  • Biochemical markers
  • Maternal serum screening

Background:

  • Down's syndrome screening is effective in early pregnancy.
  • Biochemical markers like PAPP-A and free beta-hCG are key at 10 weeks.
  • Maternal age is a crucial factor in screening accuracy.

Purpose of the Study:

  • To evaluate the effectiveness of 10-week pregnancy screening for Down's syndrome.
  • To identify optimal biochemical markers for first-trimester screening.
  • To assess the role of nuchal translucency in conjunction with biochemical markers.

Main Methods:

  • Multicentre study involving first-trimester serum screening.
  • Analysis of pregnancy associated placental protein A (PAPP-A) and free beta-hCG levels.

Related Experiment Videos

  • Inclusion of maternal age in the screening algorithm.

    • Main Results:

    • PAPP-A and free beta-hCG with maternal age yield a 62% detection rate and 5% false-positive rate.
    • Results align with systematic reviews of global literature.
    • Nuchal translucency shows association with Down's syndrome but requires further research for quantification and combined performance.

    Conclusions:

    • Ten-week screening for Down's syndrome is technically feasible.
    • Current evidence is insufficient to recommend routine implementation.
    • Further research is needed on nuchal translucency's quantitative performance and combined use with biochemical markers.